Lyric Bio develops 3D tissue-enabled bioreactors to scale donor-sourced therapeutics, starting with intravenous immunoglobulin.
Lyric Bio has raised $6.6M in total funding. The most recent round was Seed. The last funding was announced in December 2025.
Lyric Bio's investors include Draper Associates, SOSV, The Venture Collective, Lucas Venture Group, Meiji Seika Pharma.
Lyric Bio is headquartered in Palo Alto, United States.
Lyric Bio develops 3D tissue-enabled bioreactors to scale donor-sourced therapeutics, starting with intravenous immunoglobulin.
Lyric Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lyric Bio — Funding & Investors." VCBacked, December 2, 2025, https://www.vcbacked.co/company/lyric-bio. Accessed July 19, 2026.
VCBacked. (2025). Lyric Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/lyric-bio
{{cite web |title=Lyric Bio — Funding & Investors |url=https://www.vcbacked.co/company/lyric-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated